ArticleBMC complementary and alternative medicine2014
Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity.
Article in BMC complementary and alternative medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver DiseaseFrontiers in nutrition · 2022Pooled it
- Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective.Frontiers in cellular and infection microbiology · 2025Review
- Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2024Review
- Insights into the Anti-Adipogenic and Anti-Inflammatory Potentialities of Probiotics against Obesity.Nutrients · 2024Review
- Potential probiotic Lactobacillus delbrueckii subsp. lactis KUMS-Y33 suppresses adipogenesis and promotes osteogenesis in human adipose-derived mesenchymal stem cell.Scientific reports · 2024Article
- Weight Loss Supplements.Molecules (Basel, Switzerland) · 2023Review
- Characterization of autochthonous lactobacilli from goat dairy products with probiotic potential for metabolic diseases.Heliyon · 2022Article
- Probiotics: Protecting Our Health from the Gut.Microorganisms · 2022Review
- Encapsulation of Pharmaceutical and Nutraceutical Active Ingredients Using Electrospinning Processes.Nanomaterials (Basel, Switzerland) · 2021Review
- Article
- Article
- Gut Microbiome Modulation Based on Probiotic Application for Anti-Obesity: A Review on Efficacy and Validation.Microorganisms · 2019Review
- Probiotics: How Effective Are They in the Fight against Obesity?Nutrients · 2019Review
- Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity.Probiotics and antimicrobial proteins · 2017Article
- Edible Plants and Their Influence on the Gut Microbiome and Acne.International journal of molecular sciences · 2017Review
- Developmental origins of NAFLD: a womb with a clue.Nature reviews. Gastroenterology & hepatology · 2017Review
- Emerging Trends in "Smart Probiotics": Functional Consideration for the Development of Novel Health and Industrial Applications.Frontiers in microbiology · 2017Review
- Obesity and microbiota: an example of an intricate relationship.Genes & nutrition · 2017Review
- Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics.Cell & bioscience · 2017Review
- Pathophysiological role of host microbiota in the development of obesity.Nutrition journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToday the impairment of metabolism and obesity are being extensively investigated due to the significant increase of the prevalence of these diseases. There is scientific evidence that probiotics are beneficial for human health. Thus, the aim of the study was to investigate the effect of multiprobiotic "Symbiter acidophilic concentrated" on obesity parameters in the rats under experimental obesity.
methodsThe study was carried out on 60 newborn Wistar rats, divided into 3 groups, 20 animals in each (females - n = 10, males - n = 10): intact rats, monosodium glutamate (MSG-) and MSG + probiotic group. Rats of intact group were administered with saline (8 μl/g, subcutaneously (s.c.)). Newborns rats of MSG-group and MSG + probiotic group were injected with a solution of MSG (4.0 mg/g) s.c. at 2nd - 10th postnatal days. The MSG + probiotic group was treated with 140 mg/kg (1.4 × 10(10) CFU/kg) of multiprobiotic "Symbiter". MSG-group was treated with 2.5 ml/kg of water (per os) respectively. Administration was started at the age of 4 weeks just after wean and continued for 3 month intermittently alternating two-week course of introduction with two-week course of break.
resultsNeonatal treatment with MSG caused a stunted growth in both MSG-groups, which manifested with significantly smaller naso-anal length compared to adult intact rats. There was no significant difference in weight between intact and MSG-groups on 120th day. The adiponectin level in the serum of rats with MSG-induced obesity decreased by 2.43 times (p = 0.001) in males and 1.75 (p = 0.020) in females. Concentration of leptin in adipose tissue were significantly higher by 45.9% (p = 0.019) and 61.2% (p = 0.009) respectively in males and females compared to intact rats. Our study has indicated that daily oral administration of multiprobiotic to neonatal MSG-treated rats by 2-week courses led to significant reduce of total body and VAT weight with subsequent improvement in insulin sensitivity and prevention of non-alcoholic fatty liver (NAFLD) development.
conclusionsThese results have shown that periodic treatment with multiprobiotic prevents the MSG-induced obesity and NAFLD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.